Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics, Inc. (former Nasdaq: SAGE) is a Cambridge, Massachusetts-based biopharmaceutical company focused on brain health, with a particular emphasis on postpartum depression. The company reports that it developed the only two FDA-approved treatments indicated for postpartum depression and highlights ZURZUVAE (zuranolone), described as the first-and-only oral treatment for adults with postpartum depression and, in some communications, as a once-daily 14-day oral treatment.
The news flow around Sage has centered on several themes. One major area is commercial updates for ZURZUVAE, including collaboration revenue recognized under its agreement with Biogen, prescription shipment trends for women with postpartum depression, prescriber behavior among obstetrician-gynecologists, and payer coverage metrics. Regular quarterly earnings releases have discussed revenue from ZURZUVAE, other collaboration revenue, research and development spending, selling, general and administrative expenses, restructuring charges, and cash runway expectations.
Another recurring topic is Sage’s research and development pipeline. Company news has described progress with SAGE-319, an extrasynaptic-preferring GABAA receptor positive allosteric modulator being studied for behavioral symptoms associated with certain neurodevelopmental disorders, along with preclinical NMDA receptor negative allosteric modulator programs SAGE-817 and SAGE-039, and evaluation of potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies.
Corporate and strategic developments are also prominent in Sage’s news. Releases have covered a strategic alternatives review, unsolicited acquisition proposals, and, ultimately, the definitive agreement and subsequent completion of an acquisition by Supernus Pharmaceuticals, Inc. Investors reviewing SAGE-related news can use this page to follow historical earnings announcements, pipeline updates, leadership changes, strategic reviews, and the steps that led to Sage becoming a wholly owned subsidiary of Supernus.
Sage Therapeutics, Inc. (NASDAQ: SAGE) announced a live webcast scheduled for February 24, 2022, at 8:00 a.m. ET to discuss its fourth quarter and full year 2021 financial results. The event will cover recent business updates and can be accessed via Sage's investor page. A replay will be available two hours post-event for 30 days. Sage focuses on developing innovative therapies for severe brain disorders, aiming to enhance treatment approaches in depression and neurology.
Sage Therapeutics, a biopharmaceutical company focused on brain health, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 AM ET. Key presentations will be accessible via a live webcast on the company's Investor page. A replay will be available for 30 days post-event. Sage Therapeutics is dedicated to creating transformative therapies for individuals with debilitating brain disorders.
Sage Therapeutics recently announced progress in clinical studies, highlighting that SAGE-718 showed improved cognitive function in patients with Alzheimer’s disease. Additionally, they are enrolling patients for the KINETIC 2 study, focusing on SAGE-324 for essential tremor. The company will host its annual FutureCast event today to review its R&D strategy, showcasing advancements in depression and neurology programs. With a focus on GABA and NMDA receptor pathways, Sage aims to address significant brain health disorders.
Sage Therapeutics and Biogen announced promising results from their clinical program for zuranolone, an investigational treatment for major depressive disorder (MDD). In the WATERFALL Study, patients receiving 50 mg zuranolone showed rapid improvements in depressive symptoms as early as Day 3, with effects maintained through Day 42. Safety profiles were consistent with previous studies, showing no increase in adverse events typical of existing antidepressants. Results for older patients (65+) were similarly favorable. These findings were presented at the American College of Neuropsychopharmacology Congress.
Sage Therapeutics and Biogen have announced positive 12-month results for zuranolone 50 mg in the ongoing Phase 3 SHORELINE Study. The study included 199 patients with major depressive disorder (MDD), demonstrating that 74.9% responded to the initial treatment. Zuranolone was well-tolerated, with 68.8% reporting adverse events, mostly mild to moderate. Approximately 80% of responders received just one or two treatment courses over a year, showcasing the drug's potential for quick symptom relief without frequent dosing.
Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced it will host the Sage FutureCast: An R&D and Portfolio Review on December 14, from 8:00 a.m. to 10:00 a.m. ET. The event will outline the company's research and development strategies, focusing on progress in its depression, neurology, and neuropsychiatry programs, including zuranolone, SAGE-324, and SAGE-718. A live webcast will be available on Sage's investor site, with a replay accessible for up to 30 days post-event.
Sage Therapeutics, Inc. (Nasdaq: SAGE) will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET. Investors can access the live webcast via Sage's Investor page. A replay will be made available approximately two hours following the event and archived for up to 30 days. Sage focuses on developing innovative therapies aimed at transforming the lives of individuals with debilitating brain disorders, including programs in depression and neurology.
Sage Therapeutics, a biopharmaceutical company focused on innovative brain therapies, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15 at 3:20 PM ET. Interested parties can access a live webcast on the company’s investor page at investor.sagerx.com. A replay will be available two hours post-event and archived for 30 days. Sage aims to enhance brain health through its initiatives in depression, neurology, and neuropsychiatry.
Sage Therapeutics reported third-quarter 2021 results, highlighting a successful pre-NDA meeting with the FDA for zuranolone, aimed at treating MDD and PPD. The company plans to submit an NDA in the second half of 2022. Financially, Sage reported a net loss of $130.2 million, an increase from $105.7 million YoY. Revenue from ZULRESSO was $1.4 million, down from $1.6 million. R&D expenses rose to $83.5 million. Cash reserves were approximately $1.8 billion. Sage anticipates continued pipeline progress with three Phase 2 studies expected soon.
Sage Therapeutics, Inc. (NASDAQ: SAGE) will host a live webcast on November 2, 2021 at 8:00 a.m. ET to announce its third quarter 2021 financial results and provide recent business updates. Access to the webcast will be available on the investor page of Sage's website, and a replay will be archived for 30 days. Sage Therapeutics focuses on developing innovative therapies aimed at transforming the treatment of brain disorders.